METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gut bugs linked to liver damage: new study seeks answers
Knowledge-focused Not yet recruitingThis study looks at whether gut bacteria in people with fatty liver disease (MASLD) produce certain chemicals that may harm the liver. Researchers will collect stool samples from 24 adults (patients and healthy volunteers) and grow the bacteria in the lab to measure these chemica…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated May 15, 2026 11:56 UTC
-
First human test of new MASH drug begins in china
Knowledge-focused Not yet recruitingThis early-stage study tests the safety of a new drug called QL2401 in 70 healthy Chinese adults. Participants receive either the drug or a placebo to check for side effects and how the drug moves through the body. The goal is to gather essential safety data before testing the dr…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated May 06, 2026 16:13 UTC